作者: Charles C. Reed , Chi Zhang , Gregory Ian Frost , Joan Mazzarelli Sopczynski
DOI:
关键词: Biochemistry 、 Genetically modified organism 、 Interleukin 12 、 Chemistry 、 Molecule 、 Membrane bound 、 In vivo 、 Ligand (biochemistry) 、 Peptide sequence 、 Single chain
摘要: The present invention relates to modified forms of IL-12. These IL-12 may be engineered have a shortened in vivo half-life compared and/or enhanced localization biological effects that corresponding non-modified form IL- 12. Short and membrane bound provide greater therapeutic control for delivery, particular when used combination with ligand inducible delivery Modified include heterodimeric p35/p40, single chain wherein naturally occurring amino acid sequence is genetically enhance susceptibility the molecule proteolytic degradation.